Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Dry Eye Disease, Neuropathic Pain
- Main trialPhase 2
- “The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.”In the company’s words, NCT05759208 on ClinicalTrials.gov
Other drugs for Dry Eye Disease
- LicaminlimabOculis · Phase 2/3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 15 Dec 2023 | The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease | |
| Phase 2Terminated | 30 Apr 2025 | The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026